Triple Negative Breast Neoplasms: all 1,163 studies

Page 8 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.

• Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)WithdrawnNCT06246786Early Phase 1
• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
• A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast CancerWithdrawnNCT06229392Phase 1
• Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast CancerActive, not recruitingNCT06175390Phase 2
• PRO1107 in Patients With Advanced Solid TumorsTerminatedNCT06171789Phase 1/2
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsActive, not recruitingNCT06157892Phase 2
• Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled TrialStatus unknownNCT06154109Phase 2
• Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresWithdrawnNCT06084689Phase 2
• "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerTerminatedNCT06067061Phase 1/2
• Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility StudyWithdrawnNCT06057636Not applicable
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesTerminatedNCT06052852Phase 1
• A Study of ADRX-0706 in Select Advanced Solid TumorsActive, not recruitingNCT06036121Phase 1
• Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06027268Phase 2
• A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7SuspendedNCT05958199Phase 1
• Exosome as the Prognostic and Predictive Biomarker in EBC PatientsActive, not recruitingNCT05955521Not applicable
• OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast CancerActive, not recruitingNCT05949021Phase 2
• Study of LP-184 in Patients With Advanced Solid TumorsActive, not recruitingNCT05933265Phase 1/2
• A Biomarker Screening Protocol for Participants With Solid TumorsTerminatedNCT05891197
• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive, not recruitingNCT05891171Phase 1
• Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsTerminatedNCT05827614Phase 1
• Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast CancerWithdrawnNCT05809895Phase 2
• A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)Active, not recruitingNCT05809752Phase 1
• Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT05783622Phase 1
• Implantable Microdevice for TNBC - Pilot StudyWithdrawnNCT05774886Phase 1
• BRCA and NACT in TNBC PatientsCompletedNCT05750719
• Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast CancerStatus unknownNCT05747313Phase 1/2
• Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast CancerTerminatedNCT05742269
• Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint AnalysisCompletedNCT05730010
• Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast CancerStatus unknownNCT05686720Early Phase 1
• A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast CancerStatus unknownNCT05681728Phase 2
• The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel MechanismStatus unknownNCT05680662Early Phase 1
• Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerSuspendedNCT05673200Phase 1
• A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.Status unknownNCT05670925Phase 2
• Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBCActive, not recruitingNCT05645380Phase 2
• Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer PatientsCompletedNCT05632848Phase 2
• Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerActive, not recruitingNCT05620134Phase 1/2
• Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsCompletedNCT05585034Phase 1
• Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasActive, not recruitingNCT05565417Phase 1/2
• Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerCompletedNCT05555706Phase 2/3
• Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast CancerActive, not recruitingNCT05552001Phase 3
• Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast CancerStatus unknownNCT05546255Phase 2
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast CancerWithdrawnNCT05539365Phase 2
• A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsActive, not recruitingNCT05537740Phase 1
• Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDCompletedNCT05520723Phase 2
• Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCActive, not recruitingNCT05498896Phase 2
• To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast CancerStatus unknownNCT05491694Phase 2
• STEMVAC in Patients With Early Stage Triple Negative Breast CancerActive, not recruitingNCT05455658Phase 2
• A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid TumorsStatus unknownNCT05453825Phase 2
• SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerCompletedNCT05445908Phase 2
• A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast CancerStatus unknownNCT05438706Phase 2
• Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer TreatmentTerminatedNCT05435352
• A Study of NI-1801 in Patients with Mesothelin Expressing Solid CancersStatus unknownNCT05403554Phase 1
• Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast CancerStatus unknownNCT05402722Phase 2
• PhI to Solid Tumors and PhII to Locally Advanced or mTNBCCompletedNCT05390710Phase 1
• Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical TrialStatus unknownNCT05390476Phase 2
• Onvansertib + Paclitaxel In TNBCActive, not recruitingNCT05383196Phase 1/2
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382299Phase 3
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382286Phase 3
• Combination of Olaparib and Navitoclax in Women with HGSC and TNBCActive, not recruitingNCT05358639Phase 1
• SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerActive, not recruitingNCT05347134Phase 3
• Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.CompletedNCT05340413Phase 2
• A Phase II Study of Chiauranib in Combine With Capecitabine in TNBCTerminatedNCT05336721Phase 2
• CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early StageActive, not recruitingNCT05333874Early Phase 1
• A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionTerminatedNCT05325866Phase 1/2
• Cardiac Outcomes With Near-Complete Estrogen DeprivationActive, not recruitingNCT05309655Not applicable
• Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast CancerTerminatedNCT05300958Phase 2
• A Study to Investigate LYL797 in Adults With Solid TumorsTerminatedNCT05274451Phase 1
• Atezolizumab Plus CArboplatin Plus Nab-paclitaxelActive, not recruitingNCT05266937Phase 2
• Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)WithdrawnNCT05255666Phase 2
• To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT05253053Phase 1/2
• NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsTerminatedNCT05252390Phase 1
• AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast CancerStatus unknownNCT05244993Phase 2
• A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid TumorsWithdrawnNCT05234606Phase 1/2
• Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBCWithdrawnNCT05233696Phase 2
• A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.CompletedNCT05230186
• A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05227664Phase 2
• RTX-224 Monotherapy in Patients With Solid TumorsTerminatedNCT05219578Phase 1/2
• Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)Active, not recruitingNCT05215106Phase 2
• Chemo-free BRCA-targeted Neoadjuvant StrategyWithdrawnNCT05209529Phase 2
• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsTerminatedNCT05194072Phase 1
• Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.CompletedNCT05181462Phase 1/2
• Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedNCT05180006Phase 2
• Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC PatientsStatus unknownNCT05174832Phase 2
• Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast CancerActive, not recruitingNCT05169853
• Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid TumorsActive, not recruitingNCT05145907Phase 2
• A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast CancerTerminatedNCT05134194Phase 3
• Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related ImmunogenicityCompletedNCT05111067
• A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBCStatus unknownNCT05103917Phase 1/2
• Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsActive, not recruitingNCT05101096Phase 1/2
• Asian Multicenter Prospective Study of ctDNA SequencingActive, not recruitingNCT05099978
• Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast CancerStatus unknownNCT05089643Phase 2
• Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast CancerStatus unknownNCT05088057Phase 2
• A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid TumorsCompletedNCT05082610Phase 1
• ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabActive, not recruitingNCT05082259Phase 1
• CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast CancerActive, not recruitingNCT05081492Phase 1
• Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IOActive, not recruitingNCT05078047Phase 3
• Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast CancerCompletedNCT05071677
• A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)Status unknownNCT05068141Phase 2
• Breast Cancer BRCA1 Carriers: a Pilot StudyWithdrawnNCT05062174

← Triple Negative Breast Neoplasms overview